Despite similar clinical arthritis severities and bacterial loads in the kidneys, significantly reduced frequencies of bone destruction were observed in the mice treated with anti-RANKL treatments, irrespective of the time of initiation of the treatment (Figure 5, A–H). The gene discussed is TNFSF11; the disease is arthritic joint disease.